Stay updated on Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial
Sign up to get notified when there's something new on the Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial page.

Latest updates to the Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 was added to the page history, and the previously displayed funding-lapse notice (v3.4.1) was removed. The overall interface and listed study records remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check21 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and NIH operations. Introduced revision v3.4.1; the previous revision v3.4.0 is removed from the history.SummaryDifference0.5%

- Check28 days agoChange DetectedAdded a glossary toggle and color-coded change highlights (green for additions, red for deletions) on the history page. The revision label was updated to v3.4.0 and the No FEAR Act Data text was adjusted.SummaryDifference0.7%

- Check42 days agoChange DetectedA new revision entry, Revision v3.3.4, appears in the history. Revision v3.3.3 is removed from the list.SummaryDifference0.1%

- Check63 days agoChange DetectedA new Revision: v3.3.3 has been added, and the HHS Vulnerability Disclosure link along with Revision: v3.3.2 has been removed.SummaryDifference0.1%

- Check92 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2 on the page header. This is a system update and does not modify any study data, eligibility, or user actions.SummaryDifference0.1%

Stay in the know with updates to Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial page.